Research library / Rapamycin

Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results

M Moel, G Harinath, V Lee, A Nyquist, S Morgan, A Isman et al.. Aging. 2025.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

PEARL: weekly low-dose rapamycin for 48 weeks was relatively safe; visceral fat did not change; lean mass and pain improved in women on 10 mg.

Limits

Primary endpoint null; sponsor sells rapamycin.

Source

doi.org/10.18632/aging.206235 · PubMed 40188830 · Free full text

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.